Authorea (Authorea),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Dec. 15, 2022
The
emerging
issue
of
rising
gabapentinoid
misuse
is
being
recognised
alongside
the
lack
current
evidence
supporting
safe
and
effective
deprescribing
gabapentinoids.
This
scoping
review
aimed
to
assess
extent
nature
interventions
in
adults,
either
reducing
dosages,
or
prescribing
of,
Electronic
databases
were
searched
on
23rd
February
2022
without
restrictions.
Eligible
studies
included
randomised,
non-randomised
observational
that
assessed
an
intervention
at
reducing/ceasing
prescription/use
a
adults
for
any
indication
clinical
setting.
research
outcomes
investigated
type
intervention,
rates,
cessations,
patient
outcomes,
adverse
events.
Extracted
outcome
data
was
categorised
as
short
(≤
3
months),
intermediate
(>3
but
<12
months)
long
(≥
12
term.
A
narrative
synthesis
conducted.
four
conducted
primary
acute
care
settings.
Intervention
dose
protocols,
education
and/or
pharmacological-based
approaches.
In
randomised
trials,
use
could
be
ceased
least
one-third
participants.
two
rates
decreased
by
9%.
Serious
events
specifically
related
gabapentinoids
reported
one
trial.
No
study
patient-focussed
psychological
process,
nor
provided
long-term
follow-up.
highlights
existing
this
area.
Due
limited
available
data,
our
unable
make
firm
judgements
most
highlighting
need
more
Deleted Journal,
Journal Year:
2022,
Volume and Issue:
unknown
Published: Nov. 1, 2022
Objetivo.
Reducir
el
consumo
de
benzodiacepinas
en
los
pacientes
asignados
al
Centro
Salud
Daroca
(Madrid)
mediante
un
abordaje
multidisciplinar,
comunitario
y
educación
para
la
salud
grupal.
Métodos.
El
programa
constaba
tres
sesiones
informativas
prácticas
retirar
las
con
seguimiento
telefónico
oficinas
farmacia.
Se
realizó
una
difusión
activa
carteles,
folletos,
prensa
radio
locales
ayuda
diferentes
activos
zona.
Resultados.
hicieron
cinco
ediciones
94
participantes.
68,6%
abandonó
tratamiento
benzodiacepinas,
13,2%
redujo
dosis
51,9%
no
reportó
efectos
secundarios
a
6
meses
intervención.
Las
prescripciones
del
centro
disminuyeron
2,65%
2
años
(825
pacientes).
Discusión.
puede
ser
efectivo
promover
buen
uso
medicamentos,
aunque
son
necesarios
más
estudios
que
avalen
estas
estrategias.
Palabras
clave:
deprescripciones,
salud,
medicina
comunitaria.
Authorea (Authorea),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Dec. 15, 2022
The
emerging
issue
of
rising
gabapentinoid
misuse
is
being
recognised
alongside
the
lack
current
evidence
supporting
safe
and
effective
deprescribing
gabapentinoids.
This
scoping
review
aimed
to
assess
extent
nature
interventions
in
adults,
either
reducing
dosages,
or
prescribing
of,
Electronic
databases
were
searched
on
23rd
February
2022
without
restrictions.
Eligible
studies
included
randomised,
non-randomised
observational
that
assessed
an
intervention
at
reducing/ceasing
prescription/use
a
adults
for
any
indication
clinical
setting.
research
outcomes
investigated
type
intervention,
rates,
cessations,
patient
outcomes,
adverse
events.
Extracted
outcome
data
was
categorised
as
short
(≤
3
months),
intermediate
(>3
but
<12
months)
long
(≥
12
term.
A
narrative
synthesis
conducted.
four
conducted
primary
acute
care
settings.
Intervention
dose
protocols,
education
and/or
pharmacological-based
approaches.
In
randomised
trials,
use
could
be
ceased
least
one-third
participants.
two
rates
decreased
by
9%.
Serious
events
specifically
related
gabapentinoids
reported
one
trial.
No
study
patient-focussed
psychological
process,
nor
provided
long-term
follow-up.
highlights
existing
this
area.
Due
limited
available
data,
our
unable
make
firm
judgements
most
highlighting
need
more
